Scarica l'app Stockscreener
4.95
1.64%
0.08
Dopo l'orario di chiusura:
4.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire
10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World
(FHTX) Trading Report - news.stocktradersdaily.com
Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN
FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus
FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus
Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView
FHTX Exceeds Revenue Expectations and Advances Pipeline Programs | FHTX Stock News - GuruFocus
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World
Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan
Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Trading Advice - news.stocktradersdaily.com
Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):